Metformin is nowadays considered to be the first-line pharmaceutical agent in type 2 diabetes mellitus (T2DM). When used as monotherapy, it can reduce the glycosylated haemoglobin (HbA1c) level by up to 12 mmol/mol; a property that is not seen in many of the newer anti-diabetic agents. It also has the advantage of reducing the risk of cardiovascular disease in patients with T2DM when compared with sulfonylureas and insulin. Metformin is not recommended in patients with degrees of renal impairment and there is a lack of guidelines on the use of metformin in patients with stable chronic kidney disease.
Bowker, S. L., Veugelers, P., Majumdar, S. R., & Johnson, J. A. (2006). Increased cancer-related morality for patients with type 2 diabetes who use sulphonylureas or insulin. Diabetes Care, 29(2), 254–258. doi:10.2337/diacare.29.02.06.dc05-1558.
3.
BruijstensL. A.van LuinM.Buscher-JungerhansP. M. M.BoschF. H. (2008) Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. The Netherlands Journal of Medicine66(5): 185–190. Retrieved from www.njmonline.nl/getpdf.php?id=10000313.
4.
CavanaughK. L. (2007) Diabetes management issues for patients with chronic kidney disease. Clinical Diabetes25(3): 90–97. doi: 10.2337/diaclin.25.3.90.
DowlingR. J. O.GoodwinP. J.StambolicV. (2011) Understanding the benefit of metformin use in cancer treatment. BioMedCentral Medicine9: 33doi: 10.1186/1741-7015-9-33.
7.
HerringtonW. G.LevyJ. B. (2008) Metformin: Effective and safe in renal disease?International Urology and Nephrology40(2): 411–417. doi: 10.1007/s11255-008-9371-6.
8.
HirstJ. A.RobertsN. W.FarmerA. J.StevensR. J.AliR. (2012) Quantifying the effect of metformin treatment and dose on glycaemic control. Diabetes Care35(2): 446–454. doi: 10.2337/dc11-1465.
9.
HosonoK.EndoH.TakahaskiH.SugiyamaM.SakaiE.UchiyamaT.NakajimaA. (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Research3(9): 1077–1083. doi: 10.1158/1940-6207.CAPR-10-0186.
10.
InoueM.IwasakiM.OtaniT.SasazukiS.NodaM.TsuganeS. (2006) Diabetes mellitus and the risk of cancer: Results from a large-scale population-based cohort study in Japan. Archives of Internal Medicine166(17): 1871–1877.
11.
InzucchiS. E.BergenstalR. M.BuseJ. B.DiamantM.FerranniniE.NauckM.MatthewsD. R. (2012) Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care35(6): 1364–1379. doi: 10.2337/dc12-0413.
12.
KennedyL.HermanW. H. (2005) Renal status among patients using metformin in a primary care setting. Diabetes Care28(4): 922–924. doi: 102337/diacare.28.4.922.
13.
KlachkoD.Whaley-ConnellA. (2011) Use of metformin in patients with kidney and cardiovascular diseases. CardioRenal Medicine1(2): 87–95. doi: 10.1159/000327151.
14.
KwongS.C.BrubacherJ. (1998) Phenformin and lactic acidosis: A case report and review. The Journal of Emergency Medicine16(6): 881–886. doi: 10.1016/S0736-4679(98)00103-6.
15.
LipskaK. J.BaileyC. J.InzucchiS. E. (2011) Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care34(6): 1431–1437. doi: 10.2337/dc10-2361.
16.
NICE. (2009). Type 2 diabetes: The management of type 2 diabetes (partial update of CG87). Retrieved from www.nice.org.uk/CG87.
17.
NyeH. J.HerringtonW. G. (2011) Metformin: The safest hypoglycaemic agent in chronic kidney disease?Nephron Clinical Practice118(4): c380–c383. doi: 10.1159/000323739.
18.
PhilbrickA. M.ErnstM.McDanelD. L.BossM. B.MooresK. G. (2009) Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate?American Journal of Health-System Pharmacy66(22): 2017–2023. doi: 10.2146/ajhp080330.
19.
PilmoreH. (2010) Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology15(4): 412–418. doi: 10.1111/j.1440-1797.2010.01328.x.
20.
QuinnB. J.KitagawaH.MemmottR. M.GillsJ. J.DennisP. A. (2013) Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology and Metabolism24(9): 469–480. doi: 10.1016/j.tem.2013.05.004.
RizosC. V.ElisafS. (2013) Metformin and cancer. European Journal of Pharmacology705(1–3): 96–108. doi: 10.1016/j.ejphar.2013.02.038.
23.
RochaA.AlmeidaM.SantosJ.CarvalhoA. (2013) Metformin in patients with chronic kidney disease: Strengths and weaknesses. Journal of Nephrology26(1): 55–60. doi: 10.5301/jn.5000166.
24.
Rojas, L. B. A., & Gomes, M. B. (2013). Metformin: An old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome, 5, 6. doi: 10.1186/1758-5996-5-6.
25.
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 3, art. no.: CD002967. doi: 10.1002/14651858.CD002967.
26.
SharifA. (2013) Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base?Quarterly Journal of Medicine: An International Journal of Medicine106(3): 291–294. doi: 10.1093/qjmed/hct016.
27.
SoliniA.PennoG.BonoraE.FondelliC.OrsiE.TrevisanR.Renal Insufficiency and Cardiovascular Events Study Group. (2013) Age, renal dysfunction, cardiovascular disease and antihyperglycaemic treatment in type 2 diabetes mellitus. Journal of the American Geriatrics Society61(8): 1253–1261. doi: 10.1111/jgs.12381.
28.
SternerG.ElmstahlS.FridA. (2012) Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus. British Journal of Diabetes and Vascular Disease12(5): 227–231. doi: 10.1177/1474651412459544.
29.
StrattonI. M.AdlerA. I.NeilH. A. W.MatthewsD. R.ManleyS. E.CullC. A.HolmanR. R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): A prospective observational study. British Medical Journal321: 405–412. doi: 10.1136/bmj.321.7258.405.
UKPDS Group. (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet352(9131): 854–865. doi: 10.1016/S0140-6736(98)07037-8.
